Drug Profile
Rotavirus W179-9 vaccine - Merck & Co
Alternative Names: Pentavalent-rotavirus-vaccine-W179-9-Merck-and-Co; PRV-Merck-and-Co; RotaTeq; Rotavirus-vaccine-live-oral-pentavalent-W179-9-Merck-and-Co; Rotavirus-W179-9-vaccine-Merck-and-Co; RV5; V260Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Banyu; Chongqing Zhifei Biological Products; Merck & Co
- Class Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Rotavirus infections
Most Recent Events
- 05 May 2022 Merck Sharp & Dohme initiates enrollment in a phase III trial in Rotavirus infections (In infants, In volunteers) (PO) in August 2004 (NCT00092456)
- 08 May 2021 Merck Sharp and Dohme completes a phase III trial for Rotavirus infection (Prevention, In Infants) in China(NCT04481191)
- 25 Aug 2020 Merck Sharp and Dohme initiates a phase III trial for Rotavirus infection (Prevention, In Infants) in China(NCT04481191)